PubMed
Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis
A double-blind, placebo-controlled trial assessed the effect of a slow-release formulation of bezafibrate (Bezalip Mono, 400 mg daily for 3 months) on lipid profile, glucose homeostasis, platelet function, and plasma fibrinogen concentration in non-insulin-dependent (type …
- PMID: 1710742